No Data
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
Oncolytics Biotech Nears FDA Accelerated Approval
Oncolytics Biotech Provides Clinical Updates
Oncolytics Biotech Brief: Announcing "Key Progress" and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Preparing for FDA Accelerated Approval Path
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
No Data